Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-3084 in Advanced Malignancies Driven by the MAPK Pathway
NCT06287463Phase 1Terminated
- Sponsor
- Deciphera Pharmaceuticals
- Start
- May 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dcc-3084 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and 2 more (2 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Number of Participants with Dose-limiting Toxicities at 28 days and Objective Response Rate at 24 months. Started May 2024; status: terminated.
02
Drugs
dcc-3084
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)melanomacastration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06287463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287463.